Pay in 4 interest-free payments of $26.25 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
Smiles: N[C@@H](CC1C=CC=CC=1)C(=O)N1C/C(=C\C2=CC(Cl)=C(Cl)C=C2)/C(=O)/C(/C1)=C/C1=CC(Cl)=C(Cl)C=C1
Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone
01-10 μM) blocks CK1ϵ-mediated PER3 nuclear localization mediated by CK1ϵ and suppresses PER2 degradation at 1 μM
approximately 58-fold more effective than sodium stibogluconate
Ruxolitinib (S) 05 trifluoroacetate A controlled trial of leuprolideS Ruxolitinib is a less active enantiomer of Ruxolitinib, a JAK1 2 inhibitor. S Ruxolitinib was initially developed to target the constitutive activation of the JAK STAT pathway. Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. Ruxolitinib maintains its anti JAK activity by competitive
US$ 2050.00
US$ 17.00
US$ 26.00
US$ 93.50
US$ 3000.00
US$ 11.00
US$ 29.00
US$ 950.00
US$ 28.00
US$ 26.00